FY2022 Q3 Financial and R&D Update
Major R&D Pipeline: Alpha
DS-7300 (JP/US)
B7-H3-directed ADC
ESCC, CRPC, squamous NSCLC, SCLC, etc.
DS-6000 (JP/US)
CDH6-directed ADC
Renal cell carcinoma, ovarian cancer
DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors
DS-1594 (US)
Menin-MLL binding inhibitor
AML, ALL
DS-9606 (US/EU)
Target undisclosed ADC
Solid tumors
Phase 1
DS-6016 (JP)
Anti-ALK2 antibody
FOP
DS-7011 (US)
Anti-TLR7 antibody
Systemic lupus erythematosus
DS-2325 (US)
KLK5 inhibitor
Netherton syndrome
As of Jan 2023
Daiichi-Sankyo
Phase 2
Valemetostat (DS-3201)(JP/US/EU/Asia)
EZH1/2 inhibitor
PTCL
Valemetostat (DS-3201) (EU)
EZH1/2 inhibitor
BCL
DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma
DS-7300 (JP/US/EU/Asia)
B7-H3-directed ADC
ES-SCLC
DS-5141 (JP)
ENA oligonucleotides
DMD
DS-1211 (US/EU)
TNAP inhibitor
Pseudoxanthoma elasticum
DS-5670 (JP)
COVID-19 mRNA vaccine, COVID-19 (primary
vaccination, 5 to 11 aged children) (in prep.)
VN-0200 (JP)
RS virus vaccine
RS virus infection
Phase 3
Pexidartinib (JP/Asia)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor
Esaxerenone (JP)
MR blocker
Diabetic nephropathy
VN-0102/JVC-001 (JP)
Measles mumps rubella combined vaccine
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain)
COVID-19 (primary vaccination, adults)
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain), COVID-19
(primary vaccination, 12 to 17 aged children)
Quizartinib (JP/US/EU)
FLT3 inhibitor
AML 1L
Mirogabalin (CN)
a28 ligands
Filed
Diabetic peripheral neuropathic pain
VN-0107/MEDI3250 (JP)
Live attenuated influenza vaccine nasal spray
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain).
COVID-19 (booster vaccination)
Oncology
Specialty medicine
Vaccine
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
SAKIGAKE Designation (JP)
Orphan drug designation (designated in at least one country/region among JP, US and EU)
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma,
FOP: Fibrodysplasia ossificans progressiva, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma
38View entire presentation